Immunocore Holdings PLC
IMCR35.200USD
+0.200+0.57%
收盘 11/11, 16:00（美东）报价延迟15分钟
1.75B总市值
亏损市盈率 TTM
关于 Immunocore Holdings PLC 公司
Immunocore Holdings plc 是一家位于英国的商业阶段生物技术公司。该公司致力于开发 TCR 双特异性免疫疗法 ImmTAX，该疗法可动员单克隆 TCR 对抗 X 疾病，旨在治疗一系列疾病，包括癌症、自身免疫性疾病和传染病。该公司拥有一个临床阶段的全资和合作项目管线，涉及三个不同的治疗领域：肿瘤学、传染病以及自身免疫和炎症疾病。其主要产品 KIMMTRAK 是一种 TCR 治疗剂，用于治疗美国、欧盟、加拿大、澳大利亚和英国的不可切除或转移性葡萄膜黑色素瘤 (mUM) 患者。其管线产品包括 IMC-F106C、IMC-F115C、IMC-F119C、IMC-F117C、IMC-F113V、IMC-I109V、IMC-SII8AI 等。其临床项目正在针对多种癌症患者开展，包括黑色素瘤、肺癌、胃癌等。
Immunocore Holdings PLC简介
公司代码IMCR
公司名称Immunocore Holdings PLC
上市日期Feb 05, 2021
CEODr. Bahija Jallal, Ph.D.
员工数量493
证券类型Depository Receipt
年结日Feb 05
公司地址92 Park Drive Milton Park
城市ABINGDON
上市交易所NASDAQ Global Select Consolidated
国家United Kingdom
邮编OX14 4RY
电话441235438600
网址https://www.immunocore.com/
公司代码IMCR
上市日期Feb 05, 2021
CEODr. Bahija Jallal, Ph.D.
Immunocore Holdings PLC公司高管
名称
名称/职务
职务
持股
持股变动
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Tina St. Leger
Ms. Tina St. Leger
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Siddharth Kaul
Mr. Siddharth Kaul
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Peter Ratcliffe
Prof. Peter Ratcliffe
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Tina St. Leger
Ms. Tina St. Leger
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2024
FY2023
FY2023Q3
FY2023Q2
FY2022
FY2022Q3
FY2022Q2
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
226.69M
73.08%
Europe
73.22M
23.61%
International
10.08M
3.25%
Collaboration revenue
213.00K
0.07%
业务
地区
暂无数据
股东统计
更新时间: 5 小时前
更新时间: 5 小时前
持股股东
股东类型
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
14.19%
Wellington Management Company, LLP
10.31%
RTW Investments L.P.
9.78%
Fidelity Management & Research Company LLC
9.68%
PRIMECAP Management Company
7.57%
其他
48.46%
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
14.19%
Wellington Management Company, LLP
10.31%
RTW Investments L.P.
9.78%
Fidelity Management & Research Company LLC
9.68%
PRIMECAP Management Company
7.57%
其他
48.46%
股东类型
持股股东
占比
Investment Advisor
43.21%
Hedge Fund
26.55%
Investment Advisor/Hedge Fund
25.26%
Research Firm
1.83%
Venture Capital
1.20%
Private Equity
0.77%
Pension Fund
0.54%
Family Office
0.05%
Individual Investor
0.03%
其他
0.57%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
300
49.40M
99.22%
-6.80M
2025Q2
293
49.19M
99.31%
-10.02M
2025Q1
304
50.82M
102.67%
-9.36M
2024Q4
304
48.99M
99.30%
-7.33M
2024Q3
299
49.26M
99.94%
-5.38M
2024Q2
298
47.15M
96.58%
+1.62M
2024Q1
283
47.77M
97.93%
+3.51M
2023Q4
262
40.76M
86.07%
-2.70M
2023Q3
246
44.95M
95.97%
-1.86M
2023Q2
236
43.68M
94.12%
-435.38K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
T. Rowe Price Investment Management, Inc.
7.07M
14.03%
+15.84K
+0.22%
Jun 30, 2025
Wellington Management Company, LLP
5.13M
10.19%
+919.32K
+21.82%
Jul 31, 2025
RTW Investments L.P.
4.87M
9.66%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
4.82M
9.57%
+15.08K
+0.31%
Jun 30, 2025
PRIMECAP Management Company
3.77M
7.49%
+1.09M
+40.80%
Jun 30, 2025
Tang Capital Management, LLC
2.11M
4.18%
+189.90K
+9.91%
Jun 30, 2025
Bellevue Asset Management AG
2.44M
4.85%
+1.22M
+99.86%
Jun 30, 2025
Baker Bros. Advisors LP
2.32M
4.61%
--
--
Jun 30, 2025
Deep Track Capital LP
1.80M
3.57%
+388.60K
+27.53%
Jun 30, 2025
BVF Partners L.P.
1.02M
2.03%
+1.02M
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Virtus LifeSci Biotech Products ETF
1.7%
ALPS Medical Breakthroughs ETF
1.09%
Tema Oncology ETF
0.97%
SPDR S&P International Small Cap ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.15%
Invesco Nasdaq Biotechnology ETF
0.15%
iShares Biotechnology ETF
0.12%
iShares Intl Small Cap Equity Factor ETF
0.1%
SPDR Portfolio Developed World ex-US ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
查看更多
Virtus LifeSci Biotech Products ETF
占比1.7%
ALPS Medical Breakthroughs ETF
占比1.09%
Tema Oncology ETF
占比0.97%
SPDR S&P International Small Cap ETF
占比0.16%
ProShares Ultra Nasdaq Biotechnology
占比0.15%
Invesco Nasdaq Biotechnology ETF
占比0.15%
iShares Biotechnology ETF
占比0.12%
iShares Intl Small Cap Equity Factor ETF
占比0.1%
SPDR Portfolio Developed World ex-US ETF
占比0.01%
Fidelity Nasdaq Composite Index ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
